Metamark is leading a shift in urological cancer care to enable patients and their physicians to make informed tretment decisions that lead to better quality of life and lower cost of care.

LEARN MORE

Press Release

Metamark Announces Agreement with Anthem Blue Cross Blue Shield of Georgia

Metamark Genetics, Inc., a leader in providing critical diagnostic and prognostic information to enable more informed treatment decisions for urological cancer, today announced that effective May 25, 2016, the Company has signed an agreement with Anthem Blue Cross Blue Shield of Georgia.

read article
Press Release

ProMarkĀ® Prostate Cancer Prognostic now included in NCCN Guidelines

Metamark, a leader in commercializing high-value urologic oncology products, today announced that ProMarkĀ®, the first and only protein-based prognostic test for early-stage prostate cancer, has been included in the 2016 National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines.

read article
Displaying results 3-4 (of 13)
 |<  <  1 - 2 - 3 - 4 - 5 - 6 - 7  >  >|